



“THE REGULATION ON HEALTH TECHNOLOGY ASSESSMENT – WHAT’S NEXT”

22 JUNE 2022

Location

Charlemagne building, Rue de la Loi 170, 1049 Brussels, Belgium

Agenda

REGISTRATION AND WELCOME COFFEE

9:00 – 10:00

10:00 – 11:00 OPENING SESSION (Room ALCIDE DE GASPERI)

Moderator: Tamsin Rose, Friends of Europe

Stella Kyriakides, European Commissioner for Health and Food Safety (video)

Rui Santos Ivo, President of Infarmed, Portugal (past EU Presidency)

Dominique Le Guludec, President of HAS, France (current EU Presidency)

COFFEE BREAK

11:00 – 11:15

11:15 – 13:00 PLENARY SESSION (Room ALCIDE DE GASPERI)

Moderator: Tamsin Rose, Friends of Europe

After the kick off presentations, first comments are encouraged by patients’ organizations and industry associations, in particular the European Patients’ Forum (EPF), MedTech Europe (the European trade association for the medical technology industry) and EFPIA (the European Federation of Pharmaceutical Industries and Associations).

The implementation rolling plan – What’s next
Flora Giorgio, European Commission, DG SANTE

EUnetHTA21 – Supporting the future of European HTA cooperation
Marcus Guardian, National Health Care Institute, Netherlands

Joint HTA on medical devices – Looking ahead
Rosanna Tarricone, Bocconi University, Milan, Italy

Q&A Session

LUNCH BREAK

13:00 – 14:00

14:00 – 16:00 PARALLEL SESSIONS

- **Engaging with patients and clinical experts** (Room LORD JENKINS)

Moderator: Tamsin Rose, Friends of Europe

The session will discuss the involvement of patients and clinical experts in the joint work under the new EU legal framework on HTA, in particular in the joint clinical assessments and in the joint scientific consultations. It will also address the expectations of the members of the future Stakeholder Network in relation to their input to the broader strategic work, such as developing the work programmes of the Coordination Group or identifying emerging technologies.

<i>François Houÿez</i>	European Organisation for Rare Diseases (EURORDIS)
<i>Piotr Szymański</i>	European Society of Cardiology (ESC)
<i>Robin Doeswijk</i>	European Hematology Association (EHA)
<i>Alric Ruether</i>	Institute for Quality and Efficiency in Health Care (IQWiG)
<i>Chantal B�elorgey</i>	National Authority for Health (HAS)

- **Advancing HTA methodology for joint work** (Room ALCIDE DE GASPERI)

Moderator: Niklas Hedberg, EUnetHTA21 Executive Board

The panellists will reflect on their past and current experiences in carrying out joint work. The session will also address how the outcomes of past and ongoing EU-funded projects in the area of HTA, including research projects, could support the development of the methodology for joint work by the Coordination Group.

14:10 – 15:00 Joint Scientific Consultations session

<i>Antje Behring</i>	Federal Joint Committee (G-BA)
<i>Michael Berntgen</i>	European Medicines Agency, EMA
<i>Anja Schiel</i>	Norwegian Medicines Agency (NoMA)
<i>Flora Giorgio</i>	European Commission, DG SANTE

15:05 – 15:55 Joint Clinical Assessments session

<i>Chantal Guilhaume</i>	National Authority for Health (HAS)
<i>Beate Wieseler</i>	Institute for Quality and Efficiency in Health Care (IQWiG)
<i>Roisin Adams</i>	National Centre for Pharmacoeconomics (NCPE)
<i>Gerg�o Mer�esz</i>	National Institute of Pharmacy and Nutrition (NIPN)

COFFEE BREAK

16:00 – 16:30

16:30 – 16:45 Key messages from parallel sessions: counting down to 2025

Tamsin Rose and Niklas Hedberg

16:45 – 17:00 Closing remarks

Andrzej Rys, European Commission, DG SANTE